CRDF
Cardiff Oncology, Inc.
There isn't enough reported data to score CRDF yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CRDF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CRDF's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CRDF PE Valuation
CRDF has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CRDF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect CRDF's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CRDF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.55 | +$0.25 |
| Q2 2026 | -$0.60 | +$0.28 |
| Q1 2026 | -$0.67 | +$0.26 |
| Q4 2025 | -$0.69 | +$0.26 |
| Q3 2025 | -$0.80 | +$0.14 |
| Q2 2025 | -$0.88 | +$0.03 |
| Q1 2025 | -$0.93 | -$0.03 |
| Q4 2024 | -$0.95 | -$0.02 |
CRDF is still losing money, but far less than before: $0.55 per share over the past year, against $2.80 at its worst in late 2019.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CRDF on earnings quality, reporting a profit while its opponent remains loss making.
CRDF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $171K | +43% |
| Q2 2026 | $104K | -14% |
| Q1 2026 | $41K | -62% |
| Q4 2025 | $243K | +61% |
| Q3 2025 | $120K | -27% |
| Q2 2025 | $121K | -26% |
| Q1 2025 | $109K | -47% |
| Q4 2024 | $151K | -3.2% |
CRDF's revenue is growing: $171,000 last quarter, up 43% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5391% | +4587 points |
| Q2 2026 | -9245% | +2967 points |
| Q1 2026 | -31341% | -18147 points |
| Q4 2025 | -3221% | +5105 points |
| Q3 2025 | -9978% | -2341 points |
| Q2 2025 | -12212% | -4516 points |
| Q1 2025 | -13195% | -7861 points |
| Q4 2024 | -8326% | -1703 points |
CRDF's operating margin was −5391% last quarter, up 4587 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CRDF on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CRDF on profitability, with a higher operating margin.
CRDF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.9M | +$974K |
| Q4 2025 | -$6M | +$4.3M |
| Q3 2025 | -$10.9M | -$396K |
| Q4 2024 | -$10.3M | -$3.1M |
| Q3 2024 | -$10.5M | -$2.2M |
| Q2 2024 | -$9.2M | -$1.8M |
| Q1 2024 | -$7.8M | +$847K |
| Q4 2023 | -$7.1M | +$2.3M |
UNH has the stronger cash trend. Its trailing FCF is up 5.2% versus its history, compared with CRDF at down 29%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
CRDF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +7.8M shares |
| 1 year | +14% | +9.3M shares |
| 3 years | +71% | +31.5M shares |
| 5 years | +97% | +37.4M shares |
| Available history | +669% | +66.3M shares |
CRDF has 76M diluted shares, up 14% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CRDF on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CRDF Net Leverage
CRDF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CRDF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 8.2 | Oversold |
CRDF's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CRDF PE vs Healthcare Sector
CRDF has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CRDF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.96 | 24% below |
| 20 week MA | $1.01 | 28% below |
| 50 week MA | $1.57 | 54% below |
| 100 week MA | $2.35 | 69% below |
| 200 week MA | $2.29 | 68% below |
CRDF is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CRDF on trend strength, trading above more of its moving averages.
CRDF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.28 | $18.9 | +1377% |
| 2021 | $18.9 | $6.45 | -66% |
| 2022 | $6.45 | $1.26 | -80% |
| 2023 | $1.26 | $1.48 | +17% |
| 2024 | $1.48 | $4.32 | +192% |
| 2025 | $4.32 | $3.17 | -27% |
| 2026 YTD | $3.17 | $0.73 | -77% |
CRDF's yearly returns have swung widely, from +1377% in 2020 to −80% in 2022. It's down 77% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CRDF on returns for 2026, with the stronger performance.